The 14 references in paper E. Krivosheeva N., A. Komarov L., R. Shakhnovich M., I. Fedotchenkov S., E. Panchenko Р., Е. Кривошеева Н., А. Комаров Л., Р. Шахнович М., И. Федотенков С., Е. Панченко П. (2018) “КЛИНИЧЕСКИЙ РАЗБОР ПАЦИЕНТА С АНТИФОСФОЛИПИДНЫМ СИНДРОМОМ И СУБМАССИВНОЙ ТРОМБОЭМБОЛИЕЙ ЛЕГОЧНОЙ АРТЕРИИ // CLINICAL ANALYSIS OF A PATIENT WITH ANTIPHOSPHOLIPID SYNDROME AND SUB-MASSIVE PULMONARY EMBOLISM” / spz:neicon:aterotromboz:y:2018:i:1:p:76-87

1
Cohen AT, Agnelli G, Anderson FA, Arcelus JI, Bergqvist D, Brecht JG, Greer IA, Heit JA, Hutchinson JL, Kakkar AK, Mottier D, Oger E, Samama MM, Spannagl M. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007, 98(4): 756-764.
(check this in PDF content)
2
Management of massive and submassive pulmonaryembolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension.a scientific statement from the American Heart Association. Circulation, 2011, 123: 1788-1830.
(check this in PDF content)
3
Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология, 2015, 4(2)./Russian clinical guidelines for diagnosis, treatment and prevention of venous thromboembolic complications. Flebologiya, 2015, 4 (2).
(check this in PDF content)
4
Martinez C, Cohen AT, Bamber L, Rietbrock S. Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study inpatients without active cancer. Thromb Haemost, 2014, 112(2): 255-263.
(check this in PDF content)
5
Heit JA. Predicting the risk of venous thromboembolism recurrence, Am J Hematol, 2012, 87(1): 63-S67.
(check this in PDF content)
6
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal. doi: 10.1093/eurheartj/ehu283.
(check this in PDF content)
7
Meyer G, Vicaut E, Danays T, Agnelli G, Becattini C, Beyer-Westendorf J, Bluhmki E, Bouvaist H, Brenner B, Couturaud F, Dellas C, Empen K, Franca A, Galiè N, Geibel A, Goldhaber SZ, Jimenez D, Kozak M, Kupatt C, Kucher N, Lang IM, Lankeit M, Meneveau N, Pacouret G, Palazzini M, Petris A, Pruszczyk P, Rugolotto M, Salvi A, Schellong S, Sebbane M, Sobkowicz B, Stefanovic BS, Thiele H, Torbicki A, Verschuren F, Konstantinides SV. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med, 2014, 370(15): 1402-1411.
(check this in PDF content)
8
Konstantinides S, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism, J Am Coll Cardiol, 2017, 69(12): 1536-1544.
(check this in PDF content)
9
Sharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate pulmonary embolism treated with thrombolysis (from the«MOPETT»Trial). Am J Cardiol, 2013, 111: 273–277.
(check this in PDF content)
10
Wang C, Zhai Z, Yang Y, Wu Q, Cheng Z, Liang L, Dai H, Huang K, Lu W, Zhang Z, Cheng X, Shen YH, China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest, 2010, 137: 254–262.
(check this in PDF content)
11
Gupta A., Johnson D.H., Nagalla S. Antiphospholipid Antibodies. JAMA, 2017, 318(10): 959-960.
(check this in PDF content)
12
Воробьева Н.М., Ермолина О.В., Балахонова Т.В., Кириенко А.И., Панченко Е.П. Влияние продлённой терапии эноксапарином на риск рецидива венозных тромбоэмболических осложнений и реканализацию тромбированных вен. Атеротромбоз, 2015, 2: 39-50./ Vorobyova NM, Ermolina OV, Balakhonova TV, Kirienko AI, Panchenko EP. The impact of prolonged enoxaparin therapy on the risk of recurrence of venous thromboembolic complications and recanalization of thrombosed veins. Aterotromboz, 215, 2: 39-50.
(check this in PDF content)
13
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 142(6): 1698-1704.
(check this in PDF content)
14
Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, Lim W, Douketis JD. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis, 2016, 41(1):
(check this in PDF content)